Literature DB >> 28094897

Cytology assessment can predict survival for patients with metastatic pancreatic neuroendocrine neoplasms.

Carlie S Sigel1, Huimin Guo1, Keith M Sigel2, Ming Zhang1, Natasha Rekhtman1, Oscar Lin1, David S Klimstra1, Achim A Jungbluth1, Laura K Tang1.   

Abstract

BACKGROUND: Histological features and Ki-67 index have known usefulness in predicting prognosis and guiding therapy among patients with metastatic pancreatic neuroendocrine neoplasms. Fine-needle aspiration may offer advantages for Ki-67 assessment because the technique obtains highly cellular, well-preserved specimens with the potential for broader tumor sampling. In the current study, the authors evaluated concordance for grade and differentiation between concurrent core needle biopsy and cytology preparations. Cytological features and grade then were correlated with survival.
METHODS: Differentiation, grade by Ki-67 index, and correlation of these features with survival were compared between concurrent core needle biopsy and cytology specimens from 44 patients with metastatic pancreatic neuroendocrine neoplasms.
RESULTS: Differentiation by cytology smear resulted in 38 cases of well (86%) and 6 cases of poor (14%) differentiation. Agreement for differentiation between smear and cell block, smear and core needle biopsy, and cell block and core needle biopsy was 88%, 94%, and 83%, respectively, and agreement for grade was 68%, 54%, and 22%, respectively. Cytology differentiation and cytology grade were found to be strong predictors of outcome with respective hazard ratios of 8.3 (95% confidence interval [95% CI], 3.1-22.1; P<.001) and 1.9 (95% CI, 1.2-2.9) for each ascending grade. The median disease-specific survival cytology projections were 121 months (95% CI, 57-185 months [estimated]) for grade 1, 45 months (95% CI, 29-87 months) for grade 2, and 19 months (95% CI, 1-44 months) for grade 3, with median survivals of 45 months and 3 months, respectively, for patients with well-differentiated and poorly differentiated neuroendocrine tumors (P<.001).
CONCLUSIONS: Grading of pancreatic neuroendocrine neoplasms on cytology may not correlate exactly with concurrent core needle biopsy, but cytology differentiation and grade are predictive of survival based on stage-adjusted analysis. Cancer Cytopathol 2017;125:188-196.
© 2016 American Cancer Society. © 2016 American Cancer Society.

Entities:  

Keywords:  Ki-67 index; cytology; differentiation; grade; metastatic; neuroendocrine carcinoma; pancreas; pancreatic neuroendocrine tumor

Mesh:

Substances:

Year:  2017        PMID: 28094897      PMCID: PMC5352475          DOI: 10.1002/cncy.21817

Source DB:  PubMed          Journal:  Cancer Cytopathol        ISSN: 1934-662X            Impact factor:   5.284


  13 in total

1.  Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors.

Authors:  Shinichi Yachida; Efsevia Vakiani; Catherine M White; Yi Zhong; Tyler Saunders; Richard Morgan; Roeland F de Wilde; Anirban Maitra; Jessica Hicks; Angelo M Demarzo; Chanjuan Shi; Rajni Sharma; Daniel Laheru; Barish H Edil; Christopher L Wolfgang; Richard D Schulick; Ralph H Hruban; Laura H Tang; David S Klimstra; Christine A Iacobuzio-Donahue
Journal:  Am J Surg Pathol       Date:  2012-02       Impact factor: 6.394

2.  The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms.

Authors:  Olca Basturk; Zhaohai Yang; Laura H Tang; Ralph H Hruban; Volkan Adsay; Chad M McCall; Alyssa M Krasinskas; Kee-Taek Jang; Wendy L Frankel; Serdar Balci; Carlie Sigel; David S Klimstra
Journal:  Am J Surg Pathol       Date:  2015-05       Impact factor: 6.394

Review 3.  Fine-needle aspiration cytology of islet cell tumors.

Authors:  B T Collins; H M Cramer
Journal:  Diagn Cytopathol       Date:  1996-07       Impact factor: 1.582

4.  Pancreatic neuroendocrine tumour grading on endoscopic ultrasound-guided fine needle aspiration: high reproducibility and inter-observer agreement of the Ki-67 labelling index.

Authors:  B Weynand; I Borbath; V Bernard; C Sempoux; J-F Gigot; C Hubert; V Lannoy; P H Deprez; A Jouret-Mourin
Journal:  Cytopathology       Date:  2013-11-15       Impact factor: 2.073

5.  Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas.

Authors:  Laura H Tang; Brian R Untch; Diane L Reidy; Eileen O'Reilly; Deepti Dhall; Lily Jih; Olca Basturk; Peter J Allen; David S Klimstra
Journal:  Clin Cancer Res       Date:  2015-10-19       Impact factor: 12.531

6.  Pancreatic neuroendocrine tumors: accurate grading with Ki-67 index on fine-needle aspiration specimens using the WHO 2010/ENETS criteria.

Authors:  Jessica M Farrell; Judy C Pang; Grace E Kim; Z Laura Tabatabai
Journal:  Cancer Cytopathol       Date:  2014-07-09       Impact factor: 5.284

7.  DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors.

Authors:  Yuchen Jiao; Chanjuan Shi; Barish H Edil; Roeland F de Wilde; David S Klimstra; Anirban Maitra; Richard D Schulick; Laura H Tang; Christopher L Wolfgang; Michael A Choti; Victor E Velculescu; Luis A Diaz; Bert Vogelstein; Kenneth W Kinzler; Ralph H Hruban; Nickolas Papadopoulos
Journal:  Science       Date:  2011-01-20       Impact factor: 47.728

8.  Immunohistochemical staining of cytologic smears with MIB-1 helps distinguish low-grade from high-grade neuroendocrine neoplasms.

Authors:  Oscar Lin; Semra Olgac; Ileana Green; Maureen F Zakowski; David S Klimstra
Journal:  Am J Clin Pathol       Date:  2003-08       Impact factor: 2.493

9.  Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution.

Authors:  Sara Ekeblad; Britt Skogseid; Kristina Dunder; Kjell Oberg; Barbro Eriksson
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

10.  Are G3 ENETS neuroendocrine neoplasms heterogeneous?

Authors:  Fritz-Line Vélayoudom-Céphise; Pierre Duvillard; Lydia Foucan; Julien Hadoux; Cecile N Chougnet; Sophie Leboulleux; David Malka; Joël Guigay; Diane Goere; Thierry Debaere; Caroline Caramella; Martin Schlumberger; David Planchard; Dominique Elias; Michel Ducreux; Jean-Yves Scoazec; Eric Baudin
Journal:  Endocr Relat Cancer       Date:  2013-08-19       Impact factor: 5.678

View more
  4 in total

1.  Assessment of cytologic differentiation in high-grade pancreatic neuroendocrine neoplasms: A multi-institutional study.

Authors:  Carlie S Sigel; Vitor Werneck Krauss Silva; Michelle D Reid; David Chhieng; Olca Basturk; Keith M Sigel; Tanisha D Daniel; David S Klimstra; Laura H Tang
Journal:  Cancer Cytopathol       Date:  2017-10-17       Impact factor: 5.284

2.  Well differentiated grade 3 pancreatic neuroendocrine tumors compared with related neoplasms: A morphologic study.

Authors:  Carlie S Sigel; Vitor Werneck Krauss Silva; Michelle D Reid; David Chhieng; Olca Basturk; Keith M Sigel; Tanisha D Daniel; David S Klimstra; Laura H Tang
Journal:  Cancer Cytopathol       Date:  2018-02-16       Impact factor: 5.284

3.  Fibrous Extracellular Spheroids in an Endoscopic Ultrasound-Guided Pancreatic Fine Needle Aspiration Correlating to a Gyriform Pancreatic Endocrine Tumor with a Unique Cobblestone Pavement Growth Pattern.

Authors:  Alessandro Marotta; Jordan P Reynolds; Thomas P Plesec; E Rene Rodriguez; Sunguk N Jang; Maria Luisa C Policarpio-Nicolas; Bridgette Springer; Charles D Sturgis
Journal:  Case Rep Pathol       Date:  2019-10-17

Review 4.  Background features in the cytology of pancreatic neoplasms.

Authors:  Kenichi Hirabayashi; Tsubasa Saika; Naoya Nakamura
Journal:  DEN open       Date:  2022-03-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.